# Study of Adjuvant ONO-4538 With Resected Gastric Cancer

> **NCT03006705** · PHASE3 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 800 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Tegafur-gimeracil-oteracil potassium
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03006705
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2022-08-17
- **Final completion:** 2023-03-31
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2024-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006705, "Study of Adjuvant ONO-4538 With Resected Gastric Cancer". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03006705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*